Аңдатпа
Introduction. Chronic diffuse liver diseases (CDLD), including non-alcoholic and metabolically associated fatty liver disease (MAFLD), remain the leading cause of liver failure, cirrhosis, and hepatocellular carcinoma. The increasing incidence of these diseases requires not only effective clinical approaches but also systematic patient monitoring. Aim. To study the role of medical registries in monitoring, diagnosing, and treating patients with chronic diffuse liver diseases, and to evaluate international experience in this area. Materials and methods. A review of domestic and international sources was conducted, including clinical guidelines (AASLD, EASL, KASL), epidemiological studies, and descriptions of the functioning of large registries (TARGET-LD, Global Liver Registry, DELIVER, MAFLD Registry, PBC Registry). A literature search was conducted for the period from 2018 to 2025 in international scientific databases: PubMed/MEDLINE, Cochrane Library, ScienceDirect, as well as in the Wiley, Springer, Elsevier, and Karger online libraries and on the official websites of relevant organizations (EASL, AASLD, KASL, WHO). Results and discussion. Registers provide centralized data collection on patients with chronic kidney disease, facilitate standardized diagnostics, assess treatment effectiveness, stratify risks, and generate an evidence base for clinical decisions. International experience demonstrates the significant importance of such systems for developing national healthcare strategies. However, the lack of uniform standards and funding are particularly acute in resource-limited countries, leading to data fragmentation and the impossibility of conducting comparable studies. Conclusion . The creation of national registries of patients with chronic diffuse liver disease in Kazakhstan and other CIS countries will significantly improve the quality of medical care, ensure a multidisciplinary approach, and increase the effectiveness of diagnosis and treatment at all stages.